Objective: The aim of our study was to assess the comparative patient satisfaction and side-effects of the currently prescribed drugs – tamsulosin and silodosin for benign prostatic hyperplasia (BPH). Methods: A prospective study was conducted in a total of 110 BPH patients from the Department of Urology for a period of 6 months. Fifty-five patients in each group received silodosin 8 mg or tamsulosin 0.4 mg once daily. Data were collected using a suitably designed pro forma and the patient satisfaction was assessed with patient’s perception of study medication (PPSM) scale. International prostate symptom score (IPSS) was used for assessing the severity of symptoms. Results: The current study found that the treatment had a significant effect on improving scores of PPSM and IPSS at which all changes were significant at p<0.01 (paired t-test). An independent t-test showed that silodosin group had a greater improvement in PPSM scores – PPSM total by 40.4%, PPSM global by 43.7%, and PPSM pain by 0.39% which was supported by corresponding decline in IPSS scores. The side effects reported for tamsulosin were headache (5.5%), dizziness (5.5%), dry mouth (3.6%), and postural hypotension (14.4%) and those reported for silodosin were myalgia (5.5%), dizziness (7.3%), diarrhea (1.8%), and postural hypotension (10.9%). Conclusion: Patient satisfaction was improved by both the alpha blockers but silodosin showed a significantly greater increase in patient satisfaction than tamsulosin. Thus, silodosin is the better drug of choice.
To investigate the comparative patient satisfaction with Silodosin and Tamsulosin in men with lower urinary tract symptoms (LUTS) and Benign Prostate Hyperplasia and also to evaluate the impact of counselling among patients Patients and Methods: 30 patients were included in the study with 15 patients in each groups with Silodosin 8 mg once daily and Tamsulosin 0.4 mg once daily. Patients were interviewed during the first visit in the department, appropriate patient counselling was provided and were followed up in the next two visits. The patient satisfaction on treatment was assessed by using PPSM (Patient Perception of Study Medication) questionnaire and the impact of patient counseling on Quality of Life was assessed using IPSS Q8 (International Prostate Symptom Score) and BPH Impact Index (BII) at each visits. Results: Both the therapies resulted in significant improvements in PPSM, BII and IPSS scores from baseline. Assessments using the PPSM questionnaire showed that both the drugs increase patient satisfaction significantly, but between group comparisons showed that a significantly higher proportion of patients were satisfied with Silodosin therapy than Tamsulosin therapy. IPSS scores improved more significantly in Silodosin group compared to Tamsulosin group showing more symptom relief in the former group than latter. There was significant improvement in BII scores and IPSS Q8 scores showing significant improvement in patients' quality of life. Conclusions: The present data from the pilot study show that therapy with Silodosin and Tamsulosin provides significantly greater improvements in patient-reported, disease-specific QoL and treatment satisfaction but Silodosin was found to be the drug with more patient satisfaction in men with BPH symptoms and prostate enlargement. Patient counselling on BPH had an impact on the health related quality of life on both the groups.
Background: Benign prostate hyperplasia (BPH) is one of the common bothersome diseases among elderly men of age greater than 50 years. The aim of the current study was to evaluate the impact of patient counselling on quality of life (QoL), knowledge, attitude and practice (KAP) and medication adherence among patients.Methods: A Prospective study was conducted in a total of 110 BPH patients from the department of urology for a period of 6 months. 55 patients in each group received silodosin 8 mg or tamsulosin 0.4 mg once daily. Data was collected by using a suitably designed proforma, international prostate symptom score (IPSS) and BPH impact index were used for assessing QoL, morisky green levin scale for medication adherence and a suitably designed KAP questionnaire for assessing KAP. Patients were counselled regarding the disease, drugs and lifestyle modifications using patient information leaflet.Results: The current study found that both the Tamsulosin and Silodosin group had an improvement on QoL, IPSS Q 8 by 36% and 41.5% respectively and improvement on BII by 35.5% and 47.3% respectively. Medication adherence had significant improvement from first to second review by 12%. Significant improvement in knowledge by 80.1%, attitude by 72.7% and practice by 79.2% were observed.Conclusions: The provision of effective counselling was found to have a profound impact on improving patient’s quality of life, medication adherence, knowledge, attitude and practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.